What is Royalty Pharma's current debt?

Royalty Pharma (RPRX) reported current debt of $380M in Q1 2026.

How has Royalty Pharma's current debt changed year-over-year?

Royalty Pharma's current debt decreased by 61.9% year-over-year, from $998.61M to $380M.

What does current debt mean?

The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Royalty Pharma RPRX Current Debt

Current Debt at other companies

Rigel PharmaceuticalsRIGL

$22.5M—

Bristol-Myers SquibbBMY

$1.03B-78.2%

AbbVieABBV

$0-100%

BioCryst PharmaceuticalsBCRX

$1.24M-31.2%

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's current debt?: Royalty Pharma (RPRX) reported current debt of $380M in Q1 2026.
How has Royalty Pharma's current debt changed year-over-year?: Royalty Pharma's current debt decreased by 61.9% year-over-year, from $998.61M to $380M.
What does current debt mean?: The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.